Analysts Expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Will Post Earnings of -$0.02 Per Share
Wall Street brokerages predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will report ($0.02) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at $0.03. AVEO Pharmaceuticals reported earnings per share of ($0.05) in the same quarter last year, which would suggest a positive year over year growth rate of 60%. The business is scheduled to report its next quarterly earnings results on Friday, November 8th.
On average, analysts expect that AVEO Pharmaceuticals will report full year earnings of $0.01 per share for the current year, with EPS estimates ranging from ($0.02) to $0.03. For the next year, analysts forecast that the firm will post earnings of ($0.15) per share, with EPS estimates ranging from ($0.19) to ($0.12). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.04. AVEO Pharmaceuticals had a negative net margin of 46.69% and a negative return on equity of 50.69%. The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.78 million.
A number of institutional investors have recently added to or reduced their stakes in the stock. HCR Wealth Advisors purchased a new stake in AVEO Pharmaceuticals in the 1st quarter worth approximately $28,000. Cetera Advisor Networks LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter worth approximately $38,000. Anson Funds Management LP purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter worth approximately $33,000. SG Americas Securities LLC purchased a new stake in AVEO Pharmaceuticals in the 1st quarter worth approximately $50,000. Finally, Jane Street Group LLC purchased a new stake in AVEO Pharmaceuticals in the 2nd quarter worth approximately $98,000. 29.55% of the stock is owned by institutional investors.
Shares of NASDAQ AVEO traded down $0.06 during midday trading on Wednesday, hitting $0.99. 2,082,716 shares of the company’s stock traded hands, compared to its average volume of 4,631,126. AVEO Pharmaceuticals has a 1 year low of $0.49 and a 1 year high of $3.59. The stock has a market capitalization of $159.13 million, a price-to-earnings ratio of -5.21 and a beta of 0.74. The company has a debt-to-equity ratio of 6.84, a quick ratio of 2.21 and a current ratio of 2.21. The firm has a fifty day moving average of $0.72 and a 200 day moving average of $0.76.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Recommended Story: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.